D-dimer testing: A narrative review

L Wauthier, J Favresse, M Hardy, J Douxfils, G Le Gal, P M Roy, N van Es, C Ay, H Ten Cate, T Lecompte, G Lippi, F Mullier

Résultats de recherche: Contribution à un journal/une revueArticle de revueRevue par des pairs


D-dimer containing species are soluble fibrin degradation products derived from plasmin-mediated degradation of cross-linked fibrin, i.e., 'D-dimer'. D-dimer can hence be considered a biomarker of in vivo activation of both coagulation and fibrinolysis, the leading clinical application in daily practice of which is ruling out venous thromboembolism (VTE). D-dimer has been further evaluated for assessing the risk of VTE recurrence and helping define optimal duration of anticoagulation treatment in VTE, for diagnosing disseminated intravascular coagulation (DIC), and for screening those at enhanced risk of VTE. D-dimer assays should however be performed as intended by regulatory agencies, as their use outside these indications might make them a laboratory-developed test (LDT). This narrative review is aimed at: (1) reviewing the definition of D-dimer, (2) discussing preanalytical variables affecting D-dimer measurement, (3) reviewing and comparing the assays performance and some postanalytical variables (e.g., different units and age-adjusted cutoffs), and (4) discussing the interest of D-dimer measurement across different clinical settings, including pregnancy, cancer, and coronavirus disease 2019 (COVID-19).

langue originaleAnglais
Pages (de - à)151-223
Nombre de pages73
journalAdvances in clinical chemistry
Les DOIs
Etat de la publicationPublié - janv. 2023

Empreinte digitale

Examiner les sujets de recherche de « D-dimer testing: A narrative review ». Ensemble, ils forment une empreinte digitale unique.

Contient cette citation